Humans with hypomorphic mutations that dampen CSF-1R signaling might be protected from IBD and, as has been suggested by others [31], therapies inhibiting CSF-1 or CSF-1R may be beneficial in the treatment of this disease. This evidence concerns the gene CSF1 and inflammatory bowel disease.